Antihistamine: Clinical Trials

2 completed, 1 recruiting, 1 terminated. 4 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 2, Recruiting 1, Terminated 1
Phase 2	1	Recruiting 1

Follow Antihistamine: new trials by email Literature Review of Antihistamine trials Research Report on Antihistamine

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Paclitaxel, Irinotecan, Pembrolizumab - Esophageal Squamous Cell Carcinoma	Phase 1 / Phase 2	Recruiting	Merck Sharp & Dohme LLC	230	2023-05-16	2026-10-07
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer H3B-6545, Antihistamine - Breast Neoplasms	Phase 1	Completed	Eisai Co., Ltd.	33	2020-09-30	2025-10-23
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Durvalumab, Vicineum, Acetaminophen - Urinary Bladder Neoplasms	Phase 1	Completed	National Cancer Institute (NCI)	15	2018-06-07	2026-10-27
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) ARC-521 Injection, Placebo, antihistamine - Hepatitis B	Phase 1	Terminated	Arrowhead Pharmaceuticals	47	2016-06-01	2026-01-12

Conditions studied

Breast Neoplasms (1)  ·  Carcinoma in Situ (1)  ·  Esophageal Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Hepatitis B (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Arrowhead Pharmaceuticals (1)  ·  Eisai Co., Ltd. (1)  ·  Merck Sharp & Dohme LLC (1)  ·  National Cancer Institute (NCI) (1)

Countries

Japan (2)  ·  United States (2)  ·  Brazil (1)  ·  Chile (1)  ·  China (1)  ·  Germany (1)  ·  Italy (1)  ·  New Zealand (1)  ·  Norway (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  Thailand (1)  ·  Turkey (Türkiye) (1)

Top investigators

Raju Chelluri, M.D. (1)

Results publications

PMID 35642432

NIH funding

2023 (1)